NEW YORK (360Dx) – Belgian diagnostics firm MyCartis is taking aim at the point-of-care testing market with the development of its Antelope Dx platform.

Based on a silicon photonics technology developed at Ghent University, the system could enable the use to rapid, multiplexed immunoassays in the point-of-care setting but at levels of performance comparable to that provided by a conventional clinical analyzer, said Jan-Willem Hoste, a senior scientist at Ghent University and one of the inventors of the platform.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.